Literature DB >> 8317100

Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA.

P L Collins1, M A Mink, M G Hill, E Camargo, H Grosfeld, D S Stec.   

Abstract

A cDNA was constructed to encode an internally-truncated version of negative-sense genomic RNA (vRNA) of respiratory syncytial virus (RSV) containing (in 3' to 5' order) the 3' vRNA leader region, the complement of the open reading frame for bacterial chloramphenicol acetyl transferase (CAT) under the control of RSV gene-start and gene-end signals, an intergenic nucleotide, the complete L gene including the gene-start and gene-end signals, and the 5' vRNA trailer region. The encoded vRNA analog (RSV-CAT-L) would be 7502 nucleotides (nt) in length, 49.3% of the complete 15,222-nt parental vRNA. RSV-CAT-L vRNA was synthesized in vitro from HgaI-digested cDNA and transfected into RSV-infected cells. The vRNA was "rescued" such that it was expressed to yield CAT and was packaged into particles that could be passaged to express CAT in fresh cells. The efficiency of rescue was greatly improved by a single nucleotide substitution in the leader region that had been found to increase the efficiency of rescue and passage of the previously described 935-nt RSV-CAT vRNA. Compared to the 8-fold smaller RSV-CAT vRNA, and adjusted to molar equivalence of transfected RNA, RSV-CAT-L vRNA was 119- to 347-fold less efficient in expressing CAT upon transfection, whereas RSV-CAT-L vRNA containing the above-mentioned nucleotide substitution was 15.8-fold less efficient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8317100     DOI: 10.1006/viro.1993.1368

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.

Authors:  K Juhasz; B R Murphy; P L Collins
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  The activity of Sendai virus genomic and antigenomic promoters requires a second element past the leader template regions: a motif (GNNNNN)3 is essential for replication.

Authors:  C Tapparel; D Maurice; L Roux
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

3.  Identification of protein regions involved in the interaction of human respiratory syncytial virus phosphoprotein and nucleoprotein: significance for nucleocapsid assembly and formation of cytoplasmic inclusions.

Authors:  B García-Barreno; T Delgado; J A Melero
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

4.  Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication.

Authors:  Q Yu; R W Hardy; G W Wertz
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Long-term replication of Sendai virus defective interfering particle nucleocapsids in stable helper cell lines.

Authors:  W Willenbrink; W J Neubert
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end.

Authors:  S K Samal; P L Collins
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Mapping the transcription and replication promoters of respiratory syncytial virus.

Authors:  Rachel Fearns; Mark E Peeples; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Roles of the respiratory syncytial virus trailer region: effects of mutations on genome production and stress granule formation.

Authors:  Laura L Hanley; David R McGivern; Michael N Teng; Robin Djang; Peter L Collins; Rachel Fearns
Journal:  Virology       Date:  2010-08-10       Impact factor: 3.616

Review 9.  Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.

Authors:  Christian K Pfaller; Roberto Cattaneo; Matthias J Schnell
Journal:  Virology       Date:  2015-02-18       Impact factor: 3.616

10.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.